Mercator Medical outlines higher margins: what it means for Mercator Medical stock

Mercator Medical (ISIN PLMRCTR00015) generated PLN 337.2 million in consolidated sales revenue in the first half of 2026, up 16 percent year over year. On October 6, 2026, Investing.com reported that management expected margins in distribution and Thailand production to remain above 2025 levels.

Why margins matter now

The company reported PLN 57.7 million in net profit for the first half of 2026, 170 percent above the prior-year figure. EBITDA reached PLN 61.4 million, compared with negative EBITDA of PLN 0.7 million in the first half of 2025, according to Mercator Medical.

The improvement came with a cost caveat. On October 6, 2026, management said nitrite costs were more than 25 percent higher than in the first half, a pressure that could reduce production-segment results in later quarters. The same update said the cogeneration project in Thailand had reached its final implementation stage and cost about PLN 51 million.

What changed in six months

The six-month chronology shows a sharp earnings reset. On August 21, 2026, Mercator Medical published estimated second-quarter sales of about PLN 191 million and estimated EBITDA of about PLN 46 million, as reported by PPCG Stock. On September 30, 2026, the company published its first-half report. On October 6, 2026, management discussed higher margins and rising input costs.

Sales growth was concentrated in several markets. United States revenue reached PLN 136.8 million in the first half of 2026, up 29.3 percent year over year, while sales in Poland rose 17.1 percent to PLN 81 million, according to the company release. The mix gives Mercator Medical a stronger earnings base, but the cost outlook keeps margins central to the next report.

What does Thailand mean for profit

The Thailand project could reduce purchased electricity by as much as 95 percent after commissioning, according to the October 6, 2026 management update. That potential saving matters because the manufacturing segment is facing higher raw-material costs while the group expands specialist and non-glove products.

Next reporting date

The next scheduled company event is the consolidated third-quarter 2026 report on November 30, 2026, listed in Mercator Medical's investor calendar. Mercator Medical had a market capitalization of PLN 543.2 million on October 16, 2026.

The further course of trading is shown by the continuously updated real-time quote of Mercator Medical stock.

Market context: Latest market reports.

More news and analyses on Mercator Medical stock